Nitisinone

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Tyrosinemia, Type I

Conditions

Hereditary Tyrosinemia, Type I

Trial Timeline

Sep 1, 2013 → Sep 30, 2019

NCT ID

NCT02320084

About Nitisinone

Nitisinone is a pre-clinical stage product being developed by Swedish Orphan Biovitrum for Hereditary Tyrosinemia, Type I. The current trial status is completed. This product is registered under clinical trial identifier NCT02320084. Target conditions include Hereditary Tyrosinemia, Type I.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Tyrosinemia, Type I were approved

Approved (3) Terminated (0) Active (17)

✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved

✅GaradacimabCSLApproved

✅IdebenoneSanthera PharmaceuticalsApproved

🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06227429	Pre-clinical	Withdrawn	Sep 1, 2025	Jun 30, 2027	Hereditary Tyrosinemia, Type I
NCT02323529	Phase 3	Completed	Dec 1, 2014	Sep 1, 2015	Hereditary Tyrosinemia, Type I
NCT02320084	Pre-clinical	Completed	Sep 1, 2013	Sep 30, 2019	Hereditary Tyrosinemia, Type I
NCT01734889	Phase 1	Completed	Oct 1, 2012	Mar 1, 2013	Hereditary Tyrosinemia, Type I

Competing Products

20 competing products in Hereditary Tyrosinemia, Type I

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	29
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	23
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	20
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	23
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	24
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	21
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Deferasirox FCT	Novartis	Phase 2	27
Canakinumab + Placebo	Novartis	Phase 3	40
Ilaris	Novartis	Pre-clinical	33
Standard of Care for Haemophilia A	Roche	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Tafamidis	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Phase 1	29
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	18